{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:10Z","timestamp":1787589910205,"version":"build-2736575974"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtcvsopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTCVS Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xjon.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:10:46Z","timestamp":1752937846000},"page":"58-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chemical myectomy with mavacamten in patients with obstructive hypertrophic cardiomyopathy with prior septal reduction therapy: A single-center experience"],"prefix":"10.1016","volume":"27","author":[{"given":"Prabhjot","family":"Hundal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Abood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Misicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Fuad","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jamil","family":"Tajik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjon.2025.07.007_bib1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.xjon.2025.07.007_bib2","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.xjon.2025.07.007_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.amjcard.2024.10.026","article-title":"Efficacy of cardiac myosin inhibition in patients after septal reduction therapy","volume":"235","author":"Bavishi","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.xjon.2025.07.007_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xjon.2025.07.007_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.xjon.2025.07.007_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","article-title":"Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"118","author":"Sorajja","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.xjon.2025.07.007_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030607","article-title":"Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study","volume":"13","author":"Masri","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["JTCVS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666273625002360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666273625002360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:32:07Z","timestamp":1760808727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666273625002360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":7,"alternative-id":["S2666273625002360"],"URL":"https:\/\/doi.org\/10.1016\/j.xjon.2025.07.007","relation":{},"ISSN":["2666-2736"],"issn-type":[{"value":"2666-2736","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical myectomy with mavacamten in patients with obstructive hypertrophic cardiomyopathy with prior septal reduction therapy: A single-center experience","name":"articletitle","label":"Article Title"},{"value":"JTCVS Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjon.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}]}}